Buscar
NLS Pharmaceutics AG
NLSPAñadir a la lista de seguimiento
0.762USD
0.0000.00%
Cierre 07/02, 13:00（ET）Cotizaciones retrasadas 15 min
20.58MCap. mercado
--P/E TTM
Más Datos de NLS Pharmaceutics AG Compañía
NewcelX AG, formerly NLS Pharmaceutics AG, is a Switzerland-based company primarily engaged in the biotechnology industry. The Company focuses on the discovery and development of therapies for rare and complex central nervous system (CNS) disorders, including sleep and neurodevelopmental conditions. The Company offers products like Quilience, which is a clinical-stage pharmaceutical compound. It aims to support the treatment of narcolepsy by modulating monoamine neurotransmission and orexin receptor activity. The Company also develops product like Nolazol, a treatment candidate for Attention Deficit Hyperactivity Disorder (ADHD). The Company is a publicly traded company, listing on the NASDAQ.
Información de NLS Pharmaceutics AG
Símbolo de cotizaciónNLSP
Nombre de la empresaNewcelX AG
Fecha de salida a bolsaJan 29, 2021
Director ejecutivoZwyer (Alexander)
Número de empleados1
Tipo de seguridadOrdinary Share
Fin del año fiscalJan 29
DirecciónThe Circle 6
CiudadZUERICH
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísSwitzerland
Código postal8058
Teléfono41445122150
Sitio Webhttps://nlspharma.com/
Símbolo de cotizaciónNLSP
Fecha de salida a bolsaJan 29, 2021
Director ejecutivoZwyer (Alexander)
Ejecutivos de NLS Pharmaceutics AG
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Ronald Hafner
Mr. Ronald Hafner
Independent Chairman of the Board
Independent Chairman of the Board
438.17K
+29.59%
Dr. Eric Konofal, M.D., Ph.D.
Dr. Eric Konofal, M.D., Ph.D.
Chief Scientific Officer
Chief Scientific Officer
48.53K
--
Mr. Gian-Marco Rinaldi
Mr. Gian-Marco Rinaldi
Independent Director
Independent Director
12.40K
--
Ms. Florence Allouche Aknin
Ms. Florence Allouche Aknin
Independent Director
Independent Director
3.00K
--
Mr. Alexander Zwyer
Mr. Alexander Zwyer
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ms. Cindy Rizzo
Ms. Cindy Rizzo
Investor Relations
Investor Relations
--
--
Ms. Nicole Fernandez-mcgovern
Ms. Nicole Fernandez-mcgovern
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Olivier Samuel
Mr. Olivier Samuel
Independent Director
Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Ronald Hafner
Mr. Ronald Hafner
Independent Chairman of the Board
Independent Chairman of the Board
438.17K
+29.59%
Dr. Eric Konofal, M.D., Ph.D.
Dr. Eric Konofal, M.D., Ph.D.
Chief Scientific Officer
Chief Scientific Officer
48.53K
--
Mr. Gian-Marco Rinaldi
Mr. Gian-Marco Rinaldi
Independent Director
Independent Director
12.40K
--
Ms. Florence Allouche Aknin
Ms. Florence Allouche Aknin
Independent Director
Independent Director
3.00K
--
Mr. Alexander Zwyer
Mr. Alexander Zwyer
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ms. Cindy Rizzo
Ms. Cindy Rizzo
Investor Relations
Investor Relations
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de NLS Pharmaceutics AG?
Los cinco principales accionistas de NLS Pharmaceutics AG son: Mr. Ronald Hafner
¿Cuántas instituciones poseen acciones de NLS Pharmaceutics AG (NLSP)?
A fecha de 2026Q1, 14 instituciones poseen acciones de NLS Pharmaceutics AG, con un valor de mercado combinado de aproximadamente 60.72K, lo que representa el 1.14% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -124181.00.